Emil Linnet

ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation.

Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases

MedTrace is striving to minimize diagnostic uncertainty through better perfusion imaging. Perfusion imaging provides medical professionals with a functional understanding of the organs blood supply inside the patient. MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly. Our solution allows for absolute blood flow quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for non-invasive blood flow quantification. Our innovative solution is intended to making 15O-water practically available right next to the PET scanner connected to an onsite cyclotron, with a software package to quantify the myocardial blood flow and perfusion. IMPORTANT NOTICE: MedTrace’s products are not currently cleared for routine use in any markets, including both the US and Europe. In the US, 15O-water is currently under investigation as an investigational drug in a Phase 3 clinical trial. In Europe, its use is in compliance with approvals granted by national drug authorities, in accordance with the specific legislation of each member state.

ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation.

Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases

MedTrace is striving to minimize diagnostic uncertainty through better perfusion imaging. Perfusion imaging provides medical professionals with a functional understanding of the organs blood supply inside the patient. MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly. Our solution allows for absolute blood flow quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for non-invasive blood flow quantification. Our innovative solution is intended to making 15O-water practically available right next to the PET scanner connected to an onsite cyclotron, with a software package to quantify the myocardial blood flow and perfusion. IMPORTANT NOTICE: MedTrace’s products are not currently cleared for routine use in any markets, including both the US and Europe. In the US, 15O-water is currently under investigation as an investigational drug in a Phase 3 clinical trial. In Europe, its use is in compliance with approvals granted by national drug authorities, in accordance with the specific legislation of each member state.